---
title: "Understanding the Market | CSTONE PHARMA-B surged over 9% in early trading as GIC increased its stake in the company for the first time in nearly two months, bringing its shareholding ratio to 6%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261534010.md"
description: "CSTONE PHARMA-B rose over 9% in early trading, and as of the time of writing, it is up 6.11%, priced at HKD 7.29, with a transaction volume of HKD 12.048 million. On the news front, according to the latest information from the Hong Kong Stock Exchange, GIC disclosed on October 13 that it has increased its stake in CSTONE PHARMA to 6%. This marks GIC's second significant increase in less than two months—previously, on August 18, GIC had substantially increased its holdings by 80.4 million shares, costing over HKD 630 million. Notably, CSTONE PHARMA announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sugliatinib monotherapy for the treatment of adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1%, no epidermal growth factor receptor (EGFR) sensitive mutations or ALK, ROS1 genomic alterations, and have not experienced disease progression after platinum-based chemoradiotherapy (CRT)"
datetime: "2025-10-17T01:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261534010.md)
  - [en](https://longbridge.com/en/news/261534010.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261534010.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/261534010.md) | [繁體中文](https://longbridge.com/zh-HK/news/261534010.md)


# Understanding the Market | CSTONE PHARMA-B surged over 9% in early trading as GIC increased its stake in the company for the first time in nearly two months, bringing its shareholding ratio to 6%

According to Zhitong Finance APP, CSTONE PHARMA-B (02616) rose over 9% in early trading, and as of the time of publication, it is up 6.11%, priced at HKD 7.29, with a transaction volume of HKD 12.048 million.

In terms of news, according to the latest information from the Hong Kong Stock Exchange, GIC disclosed on October 13 that it has increased its stake in CSTONE PHARMA to 6%. It is reported that this is GIC's second significant increase in less than two months—previously, on August 18, GIC had significantly increased its holdings by 80.4 million shares, costing over HKD 630 million.

It is worth noting that CSTONE PHARMA announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Sugli monoclonal antibody as a monotherapy for the treatment of adult patients with unresectable stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, without epidermal growth factor receptor (EGFR) sensitive mutations or ALK, ROS1 genomic alterations, and who have not experienced disease progression after platinum-based chemoradiotherapy (CRT)

### 相关股票

- [CSTONE PHARMA-B (02616.HK)](https://longbridge.com/zh-CN/quote/02616.HK.md)

## 相关资讯与研究

- [Booker on Trump paying TSA: 'Why didn't he do this weeks ago'](https://longbridge.com/zh-CN/news/280917023.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-CN/news/281325910.md)
- [Hua Hong Semiconductor Wins SSE Acceptance for Share-Issuance Acquisition Plan](https://longbridge.com/zh-CN/news/281182290.md)
- [Cathay Pacific CEO says cutting back on capacity would be a 'last resort'](https://longbridge.com/zh-CN/news/281101224.md)
- [Volvo to become sole European importer of Lynk & Co](https://longbridge.com/zh-CN/news/281165846.md)